Contraception Clinical Trial
— HGOPYOfficial title:
A Sequential and Adaptive Experiment to Increase the Uptake of Long-acting Reversible Contraceptives in Cameroon
Verified date | April 2024 |
Source | World Bank |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey. The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers. The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.
Status | Active, not recruiting |
Enrollment | 2500 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 10 Years to 49 Years |
Eligibility | Inclusion Criteria: - Female - Ages 10-49 - Presenting at HGOPY seeking FP counseling/services - HGOPY clients referred to the family planning unit for consultation Exclusion Criteria: * No exclusion criteria |
Country | Name | City | State |
---|---|---|---|
Cameroon | Hôpital gynéco-obstétrique et pédiatrique de Yaoundé (HGOPY) | Yaoundé |
Lead Sponsor | Collaborator |
---|---|
World Bank | George Washington University, Stanford University, University of California, San Diego, University of Exeter, Yaounde Gynecology, Obstetrics and Pediatrics Hospital |
Cameroon,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The client adopted a LARC | using data from the counseling sessions | 1-day | |
Primary | The client adopted a modern contraceptive method (LARC or SARC) | using data from the counseling sessions | 1-day | |
Secondary | Was the client treated with respect by the provider during the counseling session? | Self-reported indicator variable using follow-up surveys two weeks after counseling session | 2-weeks | |
Secondary | Did the client trust the provider during the counseling session? | Self-reported indicator variable using follow-up surveys two weeks after counseling session | 2-weeks | |
Secondary | Did the health provider give information about contraceptive methods that was easy to understand during the counseling session? | Self-reported indicator variable using follow-up surveys two weeks after counseling session | 2-weeks | |
Secondary | Client satisfaction with adopted contraceptive method | using 2-week and 16-week follow-up surveys | 2-week and 16-week measurements | |
Secondary | Discontinuation of adopted contraceptive method | using 2-week, 16-week, and 52-week follow-up surveys | 2-week, 16-week, and 52-week measurements | |
Secondary | Percentage of participants with unintended pregnancy within the time frame | using 16-week and 52-week follow-up surveys | 16-week and 52-week measurements |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |